TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31568130

Group type: EXPERIMENTAL
Intervention: ESR1 SNP (TT)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ESR1 STR (<17 repeats)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: ESR1 (c.‐397T>C with (TA)n=17)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: AMHR2 (AA)
Number of subjects: 124
Study: 28703727

Group type: EXPERIMENTAL
Intervention: Self-collected samples for STI testing
Number of subjects: 1113
Study: 25623246

Group type: EXPERIMENTAL
Intervention: Dexterity training program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Theraband training program
Number of subjects: 39
Study: 23599221

Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill training (BWSTT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 50
Study: 21365044

Group type: EXPERIMENTAL
Intervention: Zirconium oxide abutments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Titanium alloy abutments
Number of subjects: 0
Study: 19488955

Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery with spinal anesthesia
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery with general anesthesia
Number of subjects: 164

Group type: COMPARATOR
Intervention: Uncomplicated vaginal delivery with local anesthesia
Number of subjects: 164

Group type: COMPARATOR
Intervention: Uncomplicated vaginal delivery with spinal saddle block
Number of subjects: 164
Study: 17348223

Group type: EXPERIMENTAL
Intervention: Low intensity ultrasound treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study: 15242993

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minilaparotomy
Number of subjects: 100
Study: 10945198

Group type: EXPERIMENTAL
Intervention: Systemic venous drainage (SV group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Portal venous drainage (PV group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both groups (SV and PV)
Number of subjects: 34
Study: 9309988

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 100 micrograms twice daily
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 micrograms twice daily
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Oral fluticasone propionate 20 mg once daily
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 8318328

Group type: EXPERIMENTAL
Intervention: Induction of anaesthesia with propofol 3‐5 mg kg‐1 followed by maintenance with halothane and an appropriate regional block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Induction and maintenance of anaesthesia with a computerized, target‐controlled infusion of propofol with a regional block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study: 2882769

Group type: EXPERIMENTAL
Intervention: neostigmine 0.07 mg kg‐1
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: edrophonium 0.8 mg kg‐1
Number of subjects: 39

Group type: COMPARATOR
Intervention: control value
Number of subjects: 39
Study: 28346315

Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Training (INT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 94
Study: 27870712

Group type: EXPERIMENTAL
Intervention: Irosustat 40 mg/d
Number of subjects: 71

Group type: COMPARATOR
Intervention: Megestrol acetate 160 mg/d
Number of subjects: 71
Study: 26455890

Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (LALI) - 180 kcal/session for women, 300 kcal/session for men at 50% of CRF; n=39
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI) - 360 kcal/session for women, 600 kcal/session for men at 50% of CRF; n=51
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI) - 360 kcal/session for women, 600 kcal/session for men at 75% of CRF; n=31
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Increasing exercise amount at fixed intensity
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Increasing exercise intensity at fixed amount
Number of subjects: 121
Study: 23620190

Group type: EXPERIMENTAL
Intervention: Anger Awareness and Expression Training (AAET)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 147
Study: 20569270

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (150 IU thrice per week for 3 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (subgroup analysis based on FSHR genotype)
Number of subjects: 105
Study: 19016015

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with simultaneous temozolomide (RT + TMZ)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Postoperative radiotherapy alone (RT)
Number of subjects: 65
Study: 16784014

Group type: EXPERIMENTAL
Intervention: Modified allergen extract of Dermatophagoides pteronyssinus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pharmacologic treatment (control group)
Number of subjects: 30
Study: 12915642

Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin tablets (1.25/250 mg)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Metformin (500 mg)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Glyburide (2.5 mg)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin tablets
Number of subjects: 486
Study: 10566359

Group type: EXPERIMENTAL
Intervention: Computerized decision support system for ventilator management
Number of subjects: 200
Study: 8750803

Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxyvitamin D3 (1 alpha‐OHD3) at a dose of 0.05 microgram/kg per day for 1 year
Number of subjects: 12
Study: 2006963

Group type: EXPERIMENTAL
Intervention: Birthing stool (experimental group)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Conventional semirecumbent position (control group)
Number of subjects: 294
Study: 6756537

Group type: EXPERIMENTAL
Intervention: SPTU circular stapling instrument
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single layer of braided polyester interrupted sutures
Number of subjects: 100
Study: 31152038

Group type: EXPERIMENTAL
Intervention: Colchicine 0.01 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Colchicine 0.005 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Colchicine (both dosages)
Number of subjects: 54
Study: 28899338

Group type: EXPERIMENTAL
Intervention: Glidescope (GL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MCL)
Number of subjects: 140
Study: 26996228

Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables (≥500 g daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: General dietary advice + fruits and vegetables
Number of subjects: 68

Group type: COMPARATOR
Intervention: General dietary advice (reference group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables
Number of subjects: 68
Study: 24706088

Group type: EXPERIMENTAL
Intervention: Flecainide (150 or 100 mg/day according to body weight)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control (no antiarrhythmic drugs)
Number of subjects: 126
Study: 22997331

Group type: EXPERIMENTAL
Intervention: Moving from a high-poverty to lower-poverty neighborhood
Number of subjects: 9000000

Group type: EXPERIMENTAL
Intervention: 1-standard deviation decline in neighborhood poverty (13 percentage points)
Number of subjects: 9000000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9000000
Study: 20665492

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18158803

Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open varicocelectomy (OV)
Number of subjects: 100
Study: 11127861

Group type: EXPERIMENTAL
Intervention: Parental response to APC
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: Phenotypic resistance to APC in both parents and sibs
Number of subjects: 1519

Group type: EXPERIMENTAL
Intervention: R2 allele of exon 13 of FV gene
Number of subjects: 1519
Study: 9069612

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MLT (20 mg/day p.o. in the evening)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80
Study: 8250350

Group type: EXPERIMENTAL
Intervention: Wright peak flow meter
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: mini‐Wright peak flow meter
Number of subjects: 457

Group type: COMPARATOR
Intervention: Comparison with European and American children
Number of subjects: 457

Group type: COMPARATOR
Intervention: Comparison with Swedish and British children
Number of subjects: 457
Study: 3082163

Group type: EXPERIMENTAL
Intervention: Omnipaque 350 mg l/ml (iohexol)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hexabrix 320 mg l/ml (ioxaglate)
Number of subjects: 53
Study: 30798775

Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to pornography
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to marijuana
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to alcohol
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Social pressure for addiction to heroin
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to gambling
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to marijuana
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to pornography
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to heroin
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Traumatic childhood events for addiction to alcohol
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to marijuana
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to heroin
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Upbringing for addiction to alcohol
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Genetics for addiction to alcohol
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Genetics for addiction to pornography
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Genetics for addiction to marijuana
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Genetics for addiction to gambling
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Genetics for addiction to heroin
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Stressful circumstances and character problems
Number of subjects: 612
Study: 26593266

Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24070115

Group type: EXPERIMENTAL
Intervention: Low-dose interferon suppository (1,000 IU) administered daily for 24 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24473588

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study: 20447654

Group type: EXPERIMENTAL
Intervention: Early supported discharge with continued rehabilitation at home (ESD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 83
Study: 18628722

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Macular grid laser
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Complete posterior vitreous detachment
Number of subjects: 88
Study: 15947913

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg/ml
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg/ml
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lidocaine 10 mg/ml with adrenaline
Number of subjects: 120
Study: 12821736

Group type: EXPERIMENTAL
Intervention: Bilateral transplantation of embryonic mesencephalic dopamine cells
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham surgery (sham craniotomies)
Number of subjects: 40
Study: 10655439

Group type: COMPARATOR
Intervention: FAC (5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FAC followed by high-dose chemotherapy (cyclophosphamide, etoposide, and cisplatin with autologous hematopoietic stem cell support)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 78
Study: 9289427

Group type: EXPERIMENTAL
Intervention: Hormonal treatment and spasmolytic drugs for patients with threatened abortion
Number of subjects: 130

Group type: COMPARATOR
Intervention: Healthy pregnant women in the first trimester of gestation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Patients with threatened abortion
Number of subjects: 130
Study: 1671631

Group type: EXPERIMENTAL
Intervention: Sulphasalazine plus prednisone (6 g/d sulphasalazine, 30 mg/d prednisone initially, tapered to 10 mg/d after 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulphasalazine alone (6 g/d, placebo for prednisone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sulphasalazine plus prednisone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulphasalazine alone
Number of subjects: 60
Study: 30690731

Group type: EXPERIMENTAL
Intervention: Experience-based probability condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Description-based probability condition
Number of subjects: 0
Study: 29100262

Group type: EXPERIMENTAL
Intervention: Cold drink
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (cold drink + dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29231518

Group type: EXPERIMENTAL
Intervention: Awn-like needle at Tiantu (CV 22)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Filiform needle
Number of subjects: 100
Study: 24500930

Group type: EXPERIMENTAL
Intervention: Triple-fortified rice (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Natural rice (n = 25)
Number of subjects: 50
Study: 22322141

Group type: EXPERIMENTAL
Intervention: Biobrane® only
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Biobrane® and autologous cell suspension using the ReCell® kit
Number of subjects: 13

Group type: COMPARATOR
Intervention: Local standard treatment (Intrasite™, Acticoat™, and Duoderm(®) dressings every 2‐3 days) with surgery at 10 days
Number of subjects: 13
Study: 18279821

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 microg vaginally
Number of subjects: 488
Study: 16170293

Group type: EXPERIMENTAL
Intervention: Acupuncture sessions plus acupressure
Number of subjects: 88

Group type: COMPARATOR
Intervention: Metoclopramide infusion supplemented by vitamin B12 complex
Number of subjects: 88
Study: 12826840

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 at a dose of up to 50 ml/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: 6% HES 200/0.5 at a dose of up to 33 ml/kg
Number of subjects: 120
Study: 10916176

Group type: EXPERIMENTAL
Intervention: Clinical equipoise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sliding-scale equipoise
Number of subjects: 0
Study: 8938603

Group type: EXPERIMENTAL
Intervention: Pharmacological agents designed to augment functional recovery of the injured spinal cord
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs evaluated through scientific and regulatory processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification scheme based on FDA regulations for drug availability
Number of subjects: 0
Study: 1510257

Group type: COMPARATOR
Intervention: Normal saline solution (3 mL)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (1 mL, diluted to 3 mL with normal saline)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (2 mL, diluted to 3 mL with normal saline)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine 1:200,000 (3 mL, diluted to 3 mL with normal saline)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EPI-15 and EPI-10 groups
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EPI-10 group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EPI-15 group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study: 6828830

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (75 Hz, 0.1 ms, voltage 5-10 V, 10 contractions of 10 seconds with 50 seconds rest)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isometric training (10 maximal contractions of 10 seconds with 50 seconds rest)
Number of subjects: 16
Study: 31066775

Group type: EXPERIMENTAL
Intervention: CTI‐TS services over a 9‐month period
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 30015544

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) with light glasses for 4 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) for 4 weeks
Number of subjects: 39
Study: 26787148

Group type: EXPERIMENTAL
Intervention: Integrated community case management (iCCM) strategy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 31
Study: 25149706

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 30
Study: 22829023

Group type: EXPERIMENTAL
Intervention: Telmisartan alone or in combination with Ramipril
Number of subjects: 31546
Study: 19439364

Group type: EXPERIMENTAL
Intervention: Modafinil (200-300 mg/day depending on weight)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 46
Study: 19102753

Group type: EXPERIMENTAL
Intervention: GINA guidelines treatment for 2 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 16184038

Group type: EXPERIMENTAL
Intervention: Counseling program encouraging abrupt cessation of breast-feeding at 4 months (group A)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Counseling program encouraging prolonged breast-feeding for the duration of the woman's own informed choice (group B)
Number of subjects: 653
Study: 12167276

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Lamivudine (3TC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Stavudine (d4T) alone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Stavudine (d4T) + Zidovudine (ZDV)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + Stavudine (d4T)
Number of subjects: 129
Study: 10588075

Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibition (part of the Sorbinil Retinopathy Trial)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Baseline variables (age and treatment assignment adjusted)
Number of subjects: 407
Study: 7496757

Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (32 degrees C) for 24-48 hours with slow rewarming
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Standard management at hypothermia
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen administered every 8 hours for 1-hour duration for a 2-week period
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard management at normothermia
Number of subjects: 500
Study: 2170930

Group type: EXPERIMENTAL
Intervention: Transcutaneous application of trinitrine
Number of subjects: 23
Study: 622696

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 83

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 83
Study: 31992802

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12, minimum 6.5 × 10^9 CFU)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 230
Study: 31831868

Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg daily for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28295959

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (first exposure)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (second exposure)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d (first and second exposure correlation)
Number of subjects: 33
Study: 26695794

Group type: EXPERIMENTAL
Intervention: Different drug therapies for type A (acute sensorineural hearing loss in low tone frequencies)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Different drug therapies for type C (acute sensorineural hearing loss in all frequencies)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Different drug therapies for type B (acute sensorineural hearing loss in high tone frequencies)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Different drug therapies for type D (total deafness)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Overall comparison of curative rates among different types
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Overall comparison of four different treatment groups
Number of subjects: 1024
Study: 23648620

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vibration training)
Number of subjects: 60
Study: 21266519

Group type: EXPERIMENTAL
Intervention: 3-year progression-free survival (PFS) / event-free survival (EFS) for aggressive NHL
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Complete response for indolent NHL
Number of subjects: 127
Study: 19846022

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study: 17298707

Group type: EXPERIMENTAL
Intervention: SYN1 (spray‐dried mixture of chicory oligofructose and long‐chain inulin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15